Mass spectrometry could allow foolproof cancer detection for pharma firms
Aug 12 2010
Researchers at the Georgia Institute of Technology applied mass spectrometry to the problem of detecting early-stage ovarian cancer - and may have overcome the obstacle faced by operators in the pharma industry due to its lack of visible symptoms.
They use hot helium plasma to vaporise a single drop of blood serum, before using mass spectrometry to map the metabolites present in the sample.
Differences between healthy patients' blood serum and that of individuals with ovarian cancer have so far led to diagnoses with 100 per cent accuracy.
Initial tests used 94 participants and registered zero false positives and zero false negatives.
However, 100 per cent of test subjects with ovarian cancer were identified using the process.
Georgia Tech professor of biology John McDonald serves as chief research scientist at Atlanta's Ovarian Cancer Institute, a facility founded to serve the "dire need" for studies into the condition.
In This Edition Modern & Practocal Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Oct 10 2023 Hybrid event
Oct 15 2023 Katowice, Poland
Nov 05 2023 Vienna, Austria
Nov 12 2023 Louisville, KY, USA
Nov 13 2023 Plainsboro, NJ, USA